Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04866134 · ClinicalTrials.gov registry record · Phase 1

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Erasca.

Active
Registry status
Phase 1
Development phase
200
Enrollment target
5
Study locations

NCT04866134 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Erasca. The registered enrollment target is 200 participants, below the 226-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (12% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04866134, a Phase 1 study of Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Erasca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
5
Study locations

Study Summary

* To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. * To determine the optimal dose and schedule of ERAS-007 monotherapy. * To evaluate antitumor activity of ERAS-007 in various solid tumors. * To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with ERAS-601. * To characterize the pharmacokinetic (PK) profile of ERAS-007 and ERAS-601 when administered in combination. * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • DRUG ERAS-601
  • DRUG ERAS-007

Study Locations (5)

Texas

  • Mary Crowley Cancer Research - Dallas
  • NEXT Oncology - San Antonio

Colorado

  • Sarah Cannon Research Institute (HealthONE) - Denver

Florida

  • Sarah Cannon Research Institute (Florida Cancer Specialists) - Sarasota

Tennessee

  • Sarah Cannon Research Institute (Tennessee Oncology) - Nashville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-05-07
Est. Completion 2025-11-01
Phase Phase 1

Sponsor

Erasca

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04866134

The ClinicalTrials.gov registry entry for NCT04866134 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (12% lower). The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which ERAS-601 is the first listed.

NCT04866134 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT04866134 about?

NCT04866134 is a clinical study titled "A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors". * To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) p...

What is the current status of trial NCT04866134?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2021-05-07. Estimated completion is 2025-11-01.

What conditions does trial NCT04866134 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT04866134?

The interventions under investigation include: ERAS-601 (DRUG), ERAS-007 (DRUG).

Who is sponsoring clinical trial NCT04866134?

This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04866134 being conducted?

This trial has 5 study locations across Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Solid Tumors

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.